Last checked at 8 Feb 2024 08:44
TOP NEWS: AstraZeneca confident after 2023 profit more than doubles
(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades10,229
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,404.00
Bid:
12,416.00
Ask:
12,418.00
Change:
44.00 (0.36%)
Spread:
2.00 (0.016%)
Open:
12,330.00
High:
12,450.00
Low:
12,316.00
Prev. Close:
12,404.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.HSBC lifts AstraZeneca target price on haematological cancer forecasts
Mon, 04th Jan 2016 13:01
(ShareCast News) - HSBC has hiked its target price for AstraZeneca shares after the pharmaceutical giant's acquisition of cancer specialist Acerta Pharma a week before Christmas.AstraZeneca revealed it had agreed to acquire a 55% stake in privately-owned Acerta for $2.5bn, with another $1.5bn due upon approval by the US of the take-over target's lead cancer drug acalabrutinib or by end-2018, whichever was soonest.With Acerta's owners having the option to sell the remaining stake to the FTSE 100 company for $3bn, the broker said it assumed this would occur in 2018, as it saw no rationale for the option to be exercised sooner rather than later.Acalabrutinib, aka ACP-196, could prove to be "best-in-class" monotherapy, the bank said.Phase II clinical data and ongoing phase III trials also meant that acalabrutinib was likely to be very competitive versus Johnson & Johnson and AbbVie's Imbruvica, currently the only drug on the market that inhibits the BTK enzyme and can treat haematological cancers.Shift towards combination therapies justifies price tagAstraZeneca has already signed a wide-ranging collaboration with Celgene to jointly develop immuno-oncology treatments for haematological cancers.Hence, "were the standard of care in some haematological cancers to move to the combination of a BTK inhibitor (such as acalabrutinib) and an anti-PDL1 (such as AstraZeneca's durvalumab), then by acquiring Acerta, AstraZeneca would gain two thirds of the overall economics of the combination (versus 30-50% of durvalumab monotherapy)," the analysts wrote."In our view, that helps justify the potential $7bn price tag for acquiring a company whose main asset has not yet been approved, not even completed phase III development."Despite including revenues from this and other recent acquisitions, 2023 revenue forecasts of circa $37bn were still around $8bn shy of AstraZeneca's 2023 target announced during the failed Pfizer bid process, the analysts noted, though this was increasingly likely to be seen as an aspirational target that diminishes in relevance through time.AZN's target price was lifted to 4,910p from the previous 4,770p, with a 'buy' rating reiterated.
More News
8 Feb 2024 07:58
AstraZeneca shares slip as Q4 profits miss forecasts
(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.
Read more8 Feb 2024 07:50
LONDON BRIEFING: Unilever sets new buyback; Astra profit surges
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.
Read more2 Feb 2024 08:38
AstraZeneca celebrates latest successful trial of acoramidis in Japan
(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.
Read more2 Feb 2024 06:22
TOP NEWS: US sends drugmakers initial offers in Medicare price talks
(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.
Read more1 Feb 2024 15:52
UK earnings, trading statements calendar - next 7 days
| Friday 2 February | |
| YouGov PLC | Trading Statement |
| Monday 5 February | |
| Home REIT PLC | Trading Statement |
| Porvair PLC | Full Year Results |
| Trident Royalties PLC | Trading Statement |
| Vodafone Group PLC | Trading Statement |
| Tuesday 6 February | |
| Alumasc Group PLC | Half Year Results |
| BP PLC | Full Year Results |
| Filtronic PLC | Half Year Results |
| Mattioli Woods PLC | Half Year Results |
| Renishaw PLC | Half Year Results |
| Virgin Money UK PLC | Trading Statement |
| Wednesday 7 February | |
| Ashmore Group PLC | Half Year Results |
| Barratt Developments PLC | Half Year Results |
| HydrogenOne Capital Growth PLC | Trading Statement |
| Phoenix Spree Deutschland Ltd | Trading Statement |
| PZ Cussons PLC | Half Year Results |
| Smurfit Kappa Group PLC | Full Year Results |
| UK Commercial Property REIT Ltd | Trading Statement |
| Thursday 8 February | |
| Anglo American PLC | Trading Statement |
| AstraZeneca PLC | Full Year Results |
| British American Tobacco PLC | Full Year Results |
| Compass Group PLC | Trading Statement |
| Redrow PLC | Half Year Results |
| SSE PLC | Trading Statement |
| Unilever PLC | Full Year Results |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
29 Jan 2024 08:19
TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US
(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.
Read more22 Jan 2024 11:45
BioNTech challenges AstraZeneca with breast cancer precision drug trial
FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.
Read more19 Jan 2024 09:28
TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH
(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.
Read more16 Jan 2024 17:17
FTSE 100 hits one-month low, precious miners biggest drag
FTSE 100 down 0.5%, FTSE 250 flat
*Read more16 Jan 2024 16:17
London close: Stocks finish lower as wage growth eases
(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.
Read more16 Jan 2024 11:58
LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth
(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.
Read more16 Jan 2024 09:14
LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more16 Jan 2024 08:15
UBS downgrades AstraZeneca to 'sell'
(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.
Read more9 Jan 2024 10:50
Novartis in advanced talks to buy Cytokinetics- source
Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
Read more